References
- Carbone P. P., Kellerhouse L. E., Gehan E. A. Plasmacytic myeloma: A study of relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. American Journal Medicine 1967; 42: 937–48
- Costa G., Engle R. L., Jr., Schilling A., Carbone P., Kochwa S., Nachman R. L., Glidewell O. For the acute leukemia group B and the Eastern Cooperative Oncology Group. Melphalan and Prednisone: an effective combination for the treatment. American Journal Medicine 1973; 54: 589–99
- Southeastern Cancer Study Group. Treatment of myeloma. Comparison of melphalan, chlorombucil and azothioprim. Archives Internal Medicine 1975; 135: 157–62
- Durie B. G. M., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–54
- Alexanian R., Balcerzak S., Bannet J. D., Gehan E. A., Hant A., Hewlett J. S., Manto R. W. Prognostic factors in multiple myeloma. Cancer 1975; 36: 1192–201
- Merlini C., Waldenstron J. G., Jayakar S. D. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 1980; 55: 1011–19
- Medical Research Council's Working Party on Leukemia in Adults. Prognostic features in the third line myelomatosis trial. British Journal of Cancer 1980; 42: 831–40
- Harley J. B., Pajak T. F., McLntyre O. R., Kochwa S., Cooper M. R., Coleman M., Cuttner J. Improved survival of increased–risk myeloma patients on combined triplealkylating-agent therapy: a study of the CALGB. Blood 1979; 54: 13–21
- Salmon S. E., Hant S., Bannet J. D., Amare M., Weik J. K., Durie B. G. M., Dixon D. O. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma. A Southwest Oncology Group study. Journal of Clinical Oncology 1983; 1: 453–61
- Chisesi T., Capnist G., Ricciardi O. Preliminary results between melphalan and multi drug combination (VMCP) in Low and High Risk multiple myeloma. Proceedings of the symposium on multiple myeloma and B lymphoprolipherative diseases (Palermo 1983, Comitato G. Ghirotti page 103 Palermo. 1983
- Chronic Leukemia-Myeloma Task Force of the National Cancer Institute. Proposed guidelines for protocol studies: II Plasmacell myeloma. Cancer 1968; 1: 17–39
- Salmon S. E., Wampler S. B. Multiple myeloma: quantitative staging and assessment of response with programmable pocket calculator. Blood 1977; 49: 379–89
- Azam L., Delamore J. W. Combination therapy for myelomatosis. British Medical Journal 1974; 4: 560–4
- Alexanian R., Dreicer R. Chemotherapy for Multiple Myeloma. Cancer 1984; 53: 583–8
- Case D. C., Lee B. J., Clarkson B. D. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M2 Protocol. American Journal Medicine 1977; 63: 897–903
- Oken M. M., Tsiatis A., Abramson N., Glick J. Comparison of standard MP with intensive VMCP therapy for the treatment of multiple myeloma (MM). Clinical Oncology 1984; 3: 270
- Bergsagel D. E., Bailay A. J., Langley G. R., Macdonald R. N., White D. F., Miller M. B. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. New England Journal Medicine 1979; 301: 743–8
- Medical Research Council's Working Party on Leukemia in Adults. Treatment comparison in the third MRC myelomatosis trial. British Journal Medicine 1980; 42: 823–30
- Hansen O. P., Clausen N. T., Drivsholm A., Loursen B. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3–drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis. Scandinavian Journal of Haematology 1985; 35: 518–24
- Pavlosky S., Saslavsky J., Pinto M. T., Palmer L., Curuchet M., Lein J. M., Garay G., Dragosky M., Oniroga-Micheo E., Huberman S. B., Pizzolatto M. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU and vincristine in untreated multiple myeloma. Journal of Clinical Oncology 1984; 2: 836–40
- Sporn J. R., McIntyre O. R. Chemotherapy of previously untreated multiple myeloma patients: An analysis of recent treatment results. Seminars in Oncology 1986; 13: 318–25
- Mandelli F., Tribaldo M., Avvisati G., Cantonetti M., Petrucci M. T., Boccadoro M., Pileri A., Marmont F., Resegotti L., Lauta V., Dammacco F. Recombinant alfa-2b Interferon as post induction therapy for responding multiple myeloma patients. M84 protocol. Cancer Treatment Review 1988; 15: 43–8
- Chisesi T., Capnist G., De Dominicis E., Dini E. A phase II study of Idarubicin (4-Demethoxydaunomycin) in advanced myeloma. European Journal Cancer Clinical Oncology 1988; 4: 681–4